公开(公告)号：EP4456904A1

公开(公告)日：2024-11-06

申请号：EP22723787.2

申请日：2022-05-03

申请人： Kurkayev, Abdula

发明人： Kurkayev, Abdula

IPC分类号： A61K33/00 ,  A61P29/00 ,  A61P31/12 ,  A61P39/00 ,  C01B33/12 ,  C01G23/08

公开(公告)号：EP3673930B1

公开(公告)日：2024-10-30

申请号：EP20158282.2

申请日：2013-06-28

发明人： CHAN, Phillip, P. ,  CAPPONI, Vincent, J. ,  GOLOBISH, Thomas, D. ,  ALI, Humayra, Begum

IPC分类号： A61M1/34 ,  A61M1/36 ,  B01J20/28 ,  A61P1/00 ,  A61P1/04 ,  A61P29/00 ,  B01J20/26 ,  A61P7/10 ,  A61P31/04 ,  A61P37/06 ,  A61P39/02

公开(公告)号：EP4424711A3

公开(公告)日：2024-10-23

申请号：EP24184659.1

申请日：2021-05-19

申请人： Institut Curie ,  Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Centre National de la Recherche Scientifique

发明人： RODRIGUEZ, Raphaël ,  MULLER, Sebastian ,  SOLIER, Stéphanie ,  WATSON, Sarah

IPC分类号： A61K33/26 ,  A61K39/395 ,  A61P29/00 ,  A61P37/02 ,  A61P39/04 ,  C07K16/28

摘要： The invention relates to methods and pharmaceutical compositions for the treatment of Cytokine Release Syndrome (CRS). The invention also relates to methods for the diagnosis of patients suffering from Cytokine Release Syndrome.The inventors investigate iron homeostasis and the role of CD44-mediated iron endocytosis in the severe inflammatory response and Cytokine Release Syndrome, particularly in SARS-CoV-2 patients. The inventors demonstrate that during activation of M1 macrophages, iron endocytosis is upregulated in a CD44-dependent manner and that CD44 protein levels increase. This effect is specific to M1 macrophages, whereas levels of the canonical iron endocytosis protein TfR1/CD71 remain unchanged. In the present invention, the inventors provide in vitro evidences towards a direct role of CD44-mediated iron endocytosis in the severe inflammatory response such as Cytokine Release Syndrome observed in SARS-CoV-2 patients. Thus, the present invention relates to an antagonist of CD44/Hyaluronic Acid pathway for use in the treatment of cytokine release syndrome in a subject in need thereof, particularly severe COVID-19-related cytokine release syndrome.

公开(公告)号：EP4427038A1

公开(公告)日：2024-09-11

申请号：EP22891063.4

申请日：2022-11-03

申请人： Lankenau Institute for Medical Research

发明人： WALLON, U., Margaretha ,  METZ, Nolan, L.

IPC分类号： G01N33/50 ,  G01N33/80 ,  G01N33/52 ,  A61K38/06 ,  A61P25/02 ,  A61P39/06 ,  C07K5/08

CPC分类号： A61P1/08 ,  G01N33/49 ,  G01N33/80 ,  G01N2800/5220130101 ,  G01N2800/700920130101 ,  G01N2800/702820130101 ,  C12Q1/26 ,  C07K5/0215

公开(公告)号：EP3860616B1

公开(公告)日：2024-08-21

申请号：EP19869744.3

申请日：2019-10-02

IPC分类号： A61K31/7052 ,  A61K31/7048 ,  A61K31/7042 ,  A61P31/04 ,  A61K31/65 ,  A61P39/00

CPC分类号： A61K31/7048 ,  A61K31/7052 ,  A61P39/00 ,  A61K31/65

公开(公告)号：EP4408440A1

公开(公告)日：2024-08-07

申请号：EP22800117.8

申请日：2022-09-29

申请人： BASF SE ,  Christian-Albrechts-Universität zu Kiel

发明人： SCHERR, Günter ,  MROWIETZ, Ulrich

IPC分类号： A61K31/795 ,  A61K45/06 ,  A61P11/00 ,  A61P31/14 ,  A61P31/04 ,  A61P31/10 ,  A61P31/16 ,  A61P31/18 ,  A61P33/00 ,  A61P35/00 ,  A61P37/00 ,  A61P39/00 ,  A01N43/00 ,  A01N47/34 ,  A01P1/00

CPC分类号： A61K31/795 ,  A61K45/06 ,  A61P31/14 ,  A61P31/16 ,  A61P31/18 ,  A61P31/10 ,  A61P31/04 ,  A61P33/00 ,  A61P35/00 ,  A61P39/00 ,  A61P11/00 ,  A61P37/00 ,  A01N47/34 ,  A01P1/00

公开(公告)号：EP4403180A1

公开(公告)日：2024-07-24

申请号：EP22870257.7

申请日：2022-09-14

申请人： Ingr Incorporated

发明人： PYEE, Jae Ho

IPC分类号： A61K36/87 ,  A61K47/12 ,  A61K47/26 ,  A61P31/04 ,  A61P17/10 ,  A61P39/06 ,  A61K8/9789 ,  A61Q17/00 ,  A61Q19/00 ,  A23L33/105

CPC分类号： A23L33/105 ,  A61P17/10 ,  A61Q17/00 ,  A61K8/9789 ,  A61Q19/00 ,  A61K36/87 ,  A61K47/12 ,  A61K47/26 ,  A61P39/06 ,  A61P31/04

摘要： The present invention relates to an antibacterial and antioxidant composition containing grape callus culture solution, as an active ingredient, comprising epsilon(ε)-viniferin, delta (δ)-viniferin, resveratrol, and the like, and, specifically, grape callus, its culture solution, and its extract according to the present invention exhibit no cytotoxicity, have significant antioxidant and antibacterial effect against Propionibacterium acnes, and have remarkable antioxidant and antibacterial effect compared to pure viniferin, in particular, and thus, the grape callus, its culture solution, and its extract can be effectively used as active ingredients in antioxidant and antibacterial compositions.

公开(公告)号：EP4161285B1

公开(公告)日：2024-07-24

申请号：EP21737706.8

申请日：2021-06-04

IPC分类号： A23K20/174 ,  A23L33/105 ,  A23L33/155 ,  A61K36/18 ,  A61P39/06 ,  C11B5/00

CPC分类号： A61P39/06 ,  C11B5/00 ,  A23K20/174 ,  A23L33/105 ,  A23L33/155 ,  A61K36/53

公开(公告)号：EP4153192B1

公开(公告)日：2024-07-24

申请号：EP21725557.9

申请日：2021-05-19

IPC分类号： A61K33/26 ,  A61K39/395 ,  A61P29/00 ,  A61P37/02 ,  A61P39/04 ,  C07K16/28

CPC分类号： A61K33/26 ,  C07K16/2884 ,  A61P29/00 ,  A61P37/02 ,  A61P39/04 ,  C07K2317/7620130101 ,  C07K2317/2420130101 ,  G01N33/53 ,  G01N2333/7058520130101 ,  G01N2800/705720130101 ,  G01N2800/5020130101 ,  G01N2333/16520130101

公开(公告)号：EP4289482A3

公开(公告)日：2024-06-19

申请号：EP23203751.5

申请日：2017-04-21

申请人： Suzhou Auzone Biological Technology Co., Ltd

发明人： ZHOU, Xinfu ,  PARIKH, Ankit ,  GARG, Sanjay

IPC分类号： A61K9/107 ,  A61K47/14 ,  A61K47/44 ,  A61K47/34 ,  A61K31/4152 ,  A61P39/06 ,  A61P9/00 ,  A61P35/00

CPC分类号： A61K31/4152 ,  A61K9/1075 ,  A61K47/34 ,  A61K47/14 ,  A61P1/00 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P15/00 ,  A61P15/08 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P31/00 ,  A61P31/18 ,  A61P35/00 ,  A61P3/10 ,  A61P37/02 ,  A61P39/06 ,  A61P7/08 ,  A61P9/00 ,  A61P9/10

摘要： An edaravone dosage form and a use thereof in preparing a drug used for treating diseases related to oxidative stress, the dosage form being selected from a lipid-based delivery system, a solid dispersion, micelles and a solubilizing agent-based preparation.